Cairo Edinio R, Friedrich Thomas, Swarts Herman G P, Knoers Nine V, Bindels René J M, Monnens Leo A, Willems Peter H G M, De Pont Jan Joep H H M, Koenderink Jan B
Department of Biochemistry, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Biochim Biophys Acta. 2008 Feb;1778(2):398-404. doi: 10.1016/j.bbamem.2007.10.009. Epub 2007 Oct 17.
Autosomal dominant renal hypomagnesemia, associated with hypocalciurea, has been linked to a G to A mutation at nucleotide position 121 in the FXYD2 gene, resulting in the substitution of Gly with Arg at residue 41 of the protein. FXYD2, also called the Na,K-ATPase gamma-subunit, binds to Na,K-ATPase and influences its cation affinities. In this paper, we provide evidence for the molecular mechanism underlying the dominant character of the disorder. Co-immunoprecipitation experiments using tagged FXYD2 proteins demonstrated that wild type FXYD2 proteins oligomerise. Moreover, FXYD2-G41R also shows oligomerisation with itself and with the wild type protein. In the case of FXYD2-G41R, however, formation of homo-oligomers was prevented by addition of DTT or introduction of the C52A mutation. Finally, we demonstrated that artificial glycosylation of the wild type FXYD2 is reduced when co-expressed with FXYD2-G41R. These data indicate that binding of FXYD2-G41R to wild type FXYD2 subunit might abrogate the routing of wild type FXYD2 to the plasma membrane thus causing the dominant nature of this mutation.
常染色体显性遗传性低镁血症,伴有低钙尿症,与FXYD2基因第121位核苷酸处的G到A突变有关,导致该蛋白第41位残基处的甘氨酸被精氨酸取代。FXYD2,也被称为钠钾ATP酶γ亚基,与钠钾ATP酶结合并影响其阳离子亲和力。在本文中,我们为该疾病显性特征的分子机制提供了证据。使用带标签的FXYD2蛋白进行的免疫共沉淀实验表明野生型FXYD2蛋白会形成寡聚体。此外,FXYD2 - G41R自身以及与野生型蛋白之间也会形成寡聚体。然而,对于FXYD2 - G41R而言,加入二硫苏糖醇(DTT)或引入C52A突变会阻止同源寡聚体的形成。最后,我们证明当与FXYD2 - G41R共表达时,野生型FXYD2的人工糖基化会减少。这些数据表明FXYD2 - G41R与野生型FXYD2亚基的结合可能会消除野生型FXYD2向质膜的转运,从而导致该突变具有显性特征。